Introduction
Gastric cancer remains one of the most challenging malignancies to treat, particularly when it advances to metastasis in the peritoneal cavity. Recent developments in cancer therapy have led to a groundbreaking phase I clinical trial that aims to uncover more effective treatments for patients with advanced gastric cancer, specifically targeting peritoneal metastasis. The trial comprises an open-label protocol to test the combination of intraperitoneal paclitaxel, intravenous cisplatin, and oral capecitabine, a promising alliance that has garnered both interest and hope within the medical community. In this comprehensive article, we delve into the innovative IPGP study protocol, its implications, and the potential it holds for those suffering from this aggressive form of cancer.
Background on Gastric Cancer and Peritoneal Metastasis
Gastric cancer often goes undetected until it reaches advanced stages, significantly worsening the prognosis. Peritoneal metastasis, the dissemination of cancer cells to the lining of the abdominal cavity, substantially contributes to the poor outcome, with limited treatment options currently available. While surgery, chemotherapy, and radiation therapy are traditional avenues of treatment, their success rates diminish drastically once the cancer has metastasized to the peritoneal surface. Consequently, there’s an urgent need for novel therapeutic strategies to improve survival and quality of life for patients battling this stage of the disease.
The IPGP Study Protocol
The IPGP (Intraperitoneal Paclitaxel, Intravenous Cisplatin, and Oral Capecitabine in Gastric Cancer) study, as reported in BMJ Open (DOI: 10.1136/bmjopen-2018-026732), is a phase I trial that uses a 3+3 expanded cohort dose escalation to identify dose-limiting toxicities associated with the novel chemotherapy regimen. The study’s authors, including Sina Vatandoust and colleagues, intend to explore the efficacy and safety of combining intraperitoneally administered paclitaxel with the systemic chemotherapy agents cisplatin and capecitabine.
Methodology
Patients with advanced gastric cancer and peritoneal metastases are enrolled in this study and have intraperitoneal catheters surgically inserted post-enrollment. The administered chemotherapy consists of up to six cycles, each lasting 21 days, with capecitabine taken orally at a dosage of 1000 mg/m2 twice a day.
The trial protocol has received approval from the appropriate ethical and regulatory bodies, including the Southern Adelaide Clinical Human Research Ethics Committee. Conducted according to international and Australian guidelines, the study fulfills requirements set forth by the Declaration of Helsinki, CPMP/ICH/135/95 guidelines annotated by TGA comments, and NHMRC codes for ethical and responsible research conduct.
Potential Impact of the IPGP Study
The IPGP study could revolutionize gastric cancer care, especially for patients who exhibit peritoneal metastasis. Should this combination therapy prove to be effective and safe, it could pave the way for new standards of care that offer tangible hope for extended survival and improved quality of life.
Keywords
1. Gastric cancer treatment
2. Peritoneal metastasis chemotherapy
3. Intraperitoneal paclitaxel gastric cancer
4. Advanced gastric cancer study
5. IPGP trial protocol
Conclusions
The ongoing phase I trial represents a bold step forward in the quest to find more effective treatments for advanced gastric cancer. The combination of intraperitoneal paclitaxel, intravenous cisplatin, and oral capecitabine may offer a new therapeutic paradigm for managing this challenging stage of the disease. As the medical community eagerly awaits the outcomes of this trial, the implications of the IPGP study protocol extend beyond mere survival rates; it encapsulates the hope and relentless pursuit of improved care for patients afflicted by advanced gastric cancer.
References
1. Vatandoust, S., et al. (2019). Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol. BMJ Open, 9(5), e026732. DOI: 10.1136/bmjopen-2018-026732
2. Kang, Y.K., et al. (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol, 20, 666–73. DOI: 10.1093/annonc/mdn717
3. Kodera, Y., et al. (2007). Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology, 54, 960–3.
4. Yamada, Y., et al. (2001). Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol, 12, 1133–7. DOI: 10.1023/A:1011680507956
5. Ishigami, H., et al. (2010). Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol, 21, 67–70. DOI: 10.1093/annonc/mdp260